← The Wire
CTMXNasdaq
CytomX Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1501989
Developing conditionally activated biologics for oncology using PROBODY technology
red 8-K · 90d
$655M
Market cap
$3.74
Last close
+10.0%
1D
+23.0%
5D
7.0M
Volume
Price · last 39 sessions-10.5%
May 4L $2.91 · H $4.18Jun 29
232
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Bylaw AmendmentJun 22, 20268-KMaterial AgreementJun 3, 20268-KResults of OperationsMay 7, 202610-Q10-QMay 7, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 20268-KCompany UpdateMar 19, 2026424B5424B5Mar 18, 2026424B5424B5Mar 16, 20268-KResults of OperationsMar 16, 202610-K10-KMar 16, 20268-KResults of OperationsNov 6, 202510-Q10-QNov 6, 20258-KCompany UpdateAug 13, 20258-KResults of OperationsAug 7, 202510-Q10-QAug 7, 20258-KExecutive Change · Shareholder VoteJun 13, 20258-KCompany UpdateMay 28, 20258-KCompany UpdateMay 13, 2025424B5424B5May 12, 20258-KResults of Operations · Company UpdateMay 12, 202510-Q10-QMay 12, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 20258-KResults of OperationsMar 6, 202510-K10-KMar 6, 20258-KDelisting NoticeFeb 26, 20258-KExecutive ChangeFeb 3, 20258-KExit / Disposal CostsJan 6, 20258-KResults of OperationsNov 7, 202410-Q10-QNov 7, 20248-KResults of OperationsAug 8, 202410-Q10-QAug 8, 20248-KExecutive ChangeJun 17, 20248-KBylaw Amendment · Shareholder VoteMay 17, 2024SC 13GSC 13GMay 13, 20248-KCompany UpdateMay 8, 20248-KResults of OperationsMay 8, 202410-Q10-QMay 8, 2024DEFA14ADEFA14AMay 1, 2024DEFA14ADEFA14AApr 4, 2024DEF 14ADEF 14AApr 4, 20248-KExecutive Change · Bylaw AmendmentMar 22, 20248-KResults of OperationsMar 11, 202410-K10-KMar 11, 20248-KResults of OperationsNov 7, 202310-Q10-QNov 7, 20238-KMaterial AgreementAug 24, 20238-KResults of OperationsAug 8, 202310-Q10-QAug 8, 20238-KMaterial Agreement · Equity IssuanceJul 3, 20238-KShareholder VoteJun 20, 20238-KResults of OperationsMay 9, 202310-Q10-QMay 9, 2023DEFA14ADEFA14AApr 27, 2023DEF 14ADEF 14AApr 27, 20238-KResults of OperationsMar 27, 202310-K10-KMar 27, 202310-K/A10-K/AMar 27, 20238-KReg FD DisclosureMar 10, 20238-KRestatementFeb 24, 20238-KMaterial AgreementJan 5, 20238-KMaterial AgreementNov 22, 20228-KResults of OperationsNov 8, 202210-Q10-QNov 8, 20228-KExecutive ChangeSep 23, 20228-KExecutive ChangeSep 13, 20228-KResults of OperationsAug 4, 202210-Q10-QAug 4, 2022SC 13GSC 13GJul 25, 20228-KExecutive Change · Exit / Disposal CostsJul 13, 2022SC 13GSC 13GJul 8, 20228-KCompany UpdateJul 6, 20228-KShareholder VoteJun 21, 20228-KResults of OperationsMay 5, 202210-Q10-QMay 5, 2022DEFA14ADEFA14AApr 27, 2022DEF 14ADEF 14AApr 27, 20228-KExecutive ChangeApr 14, 20228-KExecutive ChangeMar 23, 2022
Insider Activity
In the 90 days to Mar 17, 2026: 4 sold $1.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Mccarthy Sean A.CEO | Sell | 118,969 | $6.42 | $764K |
| Mar 17, 2026 | Belvin MarciaSVP, Chief Scientific Officer | Sell | 31,492 | $6.42 | $202K |
| Mar 17, 2026 | Chu Yu-WayeChief Medical Officer | Sell | 21,279 | $6.42 | $137K |
| Mar 17, 2026 | Ogden ChristopherChief Financial Officer | Sell | 19,323 | $6.42 | $124K |
| Nov 6, 2025 | Mccarthy Sean A.CEO | Sell | 101,793 | $4.54 | $462K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance